Table 3. Chemosensitisation of antitumour activity determined in mice bearing SW620 xenografts.

Treatment	Nadir % Starting Body weight	Time to RTV4	Delay (days)§	Enhancement (%)†
Vehicle control	96.3	6.5
KU59403 12.5 mg/kg 2× daily ×5	100	7	0.5
Etopohos (equivalent to 10 mg/kg etoposide) daily ×5	98.6	10.5	4
Etophos + KU59403 6 mg/kg 2× daily ×5	96.9	12	5.5	38
Etophos + KU59403 12.5 mg/kg 2× daily ×5	94.9	15	8.5	113§
Etophos + KU59403 25 mg/kg 2× daily ×5	93.3	18	11.5	190*
Etophos + KU59403 12.5 mg/kg 1× daily ×5 concurrent	96.5	16.5	10	150
Etophos + KU59403 12.5 mg/kg 1× daily ×5 5 hr post	94.3	10	3.5	0
Irinotecan 2.5 mg/kg daily ×5	93.6	14.5	8
KU59403 25 mg/kg daily ×5	99.7	12	5.5
Irinotecan + KU59403 25 mg/kg daily ×5	100	26	19.5	144*

^§Delay (days) is the tumour growth delay, which is calculated as the time to median relative tumour volume 4 (median RTV4) following relevant treatment minus time to median RTV4 in control mice

^†Enhancement (%) is calculated as (100*(delay combination/delay cytotoxic alone))-100

^*indicates statistically significant enhancement (p<0.05)

^§indicates marginally statistically significant enhancement (p<0.1)